RxDoctor Payments DataLook up a doctor →

Gene Saylors, MD

Medical Oncology · Charleston, SCNPI 1215155908

Payments from drug & device makers

$1,125,854in general payments, 2019–2025

Across 1,223 payments — averaging $920.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$702K
  • Merck$124K
  • Incyte Corporation$108K
  • Genentech, Inc.$65K
  • Eli Lilly$40K
  • Exelixis Inc.$32K
  • plus $54K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.96$702,242
Merck137$123,757
Incyte Corporation39$107,512
Genentech, Inc.12$65,463
Eli Lilly2$40,204
Exelixis Inc.21$31,925
Pfizer73$16,967
Gilead(2 entities)32$8,966
Bayer16$7,773
AstraZeneca(2 entities)60$4,562
Novartis75$1,443
Johnson & Johnson(2 entities)51$930
Sanofi34$880
Amgen36$816
Genentech USA, Inc.43$766
Takeda Pharmaceuticals U.S.A., Inc.28$690
US Oncology Corporate, Inc.5$637
Mckesson Specialty Care Distribution, LLC10$629
Lilly USA, LLC28$614
Bristol Myers Squibb32$600
Regeneron Healthcare Solutions, Inc.29$566
Daiichi Sankyo Inc.18$537
Eisai Inc.24$480
Seagen Inc.27$428
Epizyme, Inc.6$390
Rigel Pharmaceuticals, Inc.18$368
GSK19$358
Jazz Pharmaceuticals Inc.17$342
Taiho Oncology, Inc.15$306
Servier Pharmaceuticals LLC9$285
Ipsen Biopharmaceuticals, Inc12$272
AbbVie13$235
Puma Biotechnology, Inc.12$219
Astellas Pharma US Inc10$212
Karyopharm Therapeutics Inc.9$182
Array Biopharma Inc12$176
Inari Medical, Inc.1$168
Boehringer Ingelheim6$160
Pharmacosmos Therapeutics Inc.5$160
ADC Therapeutics America, Inc.7$133
Alnylam Pharmaceuticals Inc.6$123
Acrotech Biopharma Inc.5$123
Sobi, Inc5$97
Pharmaessentia USA Corporation4$92
Foundation Medicine, Inc.1$89
Adaptive Biotechnologies Corporation3$84
Sanofi-aventis U.S. LLC2$84
Secura Bio, Inc.7$83
Pharmacyclics LLC, An Abbvie Company5$79
Geron Corporation3$76
EMD Serono, Inc.5$76
Fennec Pharmaceuticals, Inc.3$70
Stemline Therapeutics Inc.3$67
AVEO Pharmaceuticals, Inc.3$66
Beone Medicines USA, Inc.2$66
Iovance Biotherapeutics, Inc.2$64
Lexicon Pharmaceuticals, Inc.4$59
Morphosys, US Inc.3$54
Legend Biotech USA Inc.1$51
Beigene USA, Inc.3$49

How this compares

$1,125,854 in reported general payments places this provider in the 90th percentile of 29 medical oncology providers in South Carolina.

See all medical oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$53,201
Medicare patients
216
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →